0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Age-Related Macular Degeneration (AMD) AI Screening System Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-6S17315
Home | Market Reports | People & Society
Global Age Related Macular Degeneration AMD AI Screening System Market Research Report 2024
BUY CHAPTERS

Global Age-Related Macular Degeneration (AMD) AI Screening System Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-6S17315
Report
November 2025
Pages:132
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Age-Related Macular Degeneration (AMD) AI Screening System Market Size

AI Screening System market is projected to grow from US$ 85.6 million in 2024 to US$ 5368 million by 2031, at a CAGR of 81.8% (2025-2031), driven by critical product segments and diverse end‑use applications.

Age-Related Macular Degeneration (AMD) AI Screening System Market

Age-Related Macular Degeneration (AMD) AI Screening System Market

The global Age-Related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) represents one of leading cause of visual impairment in developed countries and a major target for AI-based approaches. The analysis of AMD data is mainly based on optical coherence tomography(OCT) images; thus, image segmentation is a fundamental step for accurately recognizing retinal structures. Many unsupervised AI-based segmentation algorithms have been developed, providing very high performance in detecting retinal features. These algorithms are useful not only for assessing the integrity of retinal structures, but also for localizing and quantifying retinal fluids during follow-up.
The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Age-Related Macular Degeneration (AMD) AI Screening System market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Age-Related Macular Degeneration (AMD) AI Screening System Market Report

Report Metric Details
Report Name Age-Related Macular Degeneration (AMD) AI Screening System Market
Accounted market size in 2024 US$ 85.6 million
Forecasted market size in 2031 US$ 5368 million
CAGR 81.8%
Base Year 2024
Forecasted years 2025 - 2031
Segment by Type
  • Hardware
  • Software
Segment by Application
  • Medical Institutions
  • Great Health Scene
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Airdoc Technology, Digital Diagnostics, Eyenuk, RetinaLyze System, Optomed, Sibionics Technology, Aeye Health, VUNO, Medimaging Integrated Solution, EyRIS (SELENA+), Vistel, RETINA-AI Health, Acer Medical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Age-Related Macular Degeneration (AMD) AI Screening System study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

How fast is Age-Related Macular Degeneration (AMD) AI Screening System Market growing?

Ans: The Age-Related Macular Degeneration (AMD) AI Screening System Market witnessing a CAGR of 81.8% during the forecast period 2025-2031.

What is the Age-Related Macular Degeneration (AMD) AI Screening System Market size in 2031?

Ans: The Age-Related Macular Degeneration (AMD) AI Screening System Market size in 2031 will be US$ 5368 million.

Who are the main players in the Age-Related Macular Degeneration (AMD) AI Screening System Market report?

Ans: The main players in the Age-Related Macular Degeneration (AMD) AI Screening System Market are Airdoc Technology, Digital Diagnostics, Eyenuk, RetinaLyze System, Optomed, Sibionics Technology, Aeye Health, VUNO, Medimaging Integrated Solution, EyRIS (SELENA+), Vistel, RETINA-AI Health, Acer Medical

What are the Application segmentation covered in the Age-Related Macular Degeneration (AMD) AI Screening System Market report?

Ans: The Applications covered in the Age-Related Macular Degeneration (AMD) AI Screening System Market report are Medical Institutions, Great Health Scene

What are the Type segmentation covered in the Age-Related Macular Degeneration (AMD) AI Screening System Market report?

Ans: The Types covered in the Age-Related Macular Degeneration (AMD) AI Screening System Market report are Hardware, Software

1 Study Coverage
1.1 Introduction to Age-Related Macular Degeneration (AMD) AI Screening System: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Hardware
1.2.3 Software
1.3 Market Segmentation by Application
1.3.1 Global Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Medical Institutions
1.3.3 Great Health Scene
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue Estimates and Forecasts 2020-2031
2.2 Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Age-Related Macular Degeneration (AMD) AI Screening System Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Age-Related Macular Degeneration (AMD) AI Screening System Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Hardware Market Size by Players
3.3.2 Software Market Size by Players
3.4 Global Age-Related Macular Degeneration (AMD) AI Screening System Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Type (2020-2031)
6.4 North America Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Type (2020-2031)
7.4 Europe Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Type (2020-2031)
8.4 Asia-Pacific Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Type (2020-2031)
9.4 Central and South America Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Type (2020-2031)
10.4 Middle East and Africa Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Age-Related Macular Degeneration (AMD) AI Screening System Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Airdoc Technology
11.1.1 Airdoc Technology Corporation Information
11.1.2 Airdoc Technology Business Overview
11.1.3 Airdoc Technology Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.1.4 Airdoc Technology Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.1.5 Airdoc Technology Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Product in 2024
11.1.6 Airdoc Technology Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Application in 2024
11.1.7 Airdoc Technology Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Geographic Area in 2024
11.1.8 Airdoc Technology Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
11.1.9 Airdoc Technology Recent Developments
11.2 Digital Diagnostics
11.2.1 Digital Diagnostics Corporation Information
11.2.2 Digital Diagnostics Business Overview
11.2.3 Digital Diagnostics Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.2.4 Digital Diagnostics Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.2.5 Digital Diagnostics Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Product in 2024
11.2.6 Digital Diagnostics Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Application in 2024
11.2.7 Digital Diagnostics Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Geographic Area in 2024
11.2.8 Digital Diagnostics Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
11.2.9 Digital Diagnostics Recent Developments
11.3 Eyenuk
11.3.1 Eyenuk Corporation Information
11.3.2 Eyenuk Business Overview
11.3.3 Eyenuk Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.3.4 Eyenuk Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.3.5 Eyenuk Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Product in 2024
11.3.6 Eyenuk Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Application in 2024
11.3.7 Eyenuk Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Geographic Area in 2024
11.3.8 Eyenuk Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
11.3.9 Eyenuk Recent Developments
11.4 RetinaLyze System
11.4.1 RetinaLyze System Corporation Information
11.4.2 RetinaLyze System Business Overview
11.4.3 RetinaLyze System Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.4.4 RetinaLyze System Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.4.5 RetinaLyze System Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Product in 2024
11.4.6 RetinaLyze System Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Application in 2024
11.4.7 RetinaLyze System Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Geographic Area in 2024
11.4.8 RetinaLyze System Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
11.4.9 RetinaLyze System Recent Developments
11.5 Optomed
11.5.1 Optomed Corporation Information
11.5.2 Optomed Business Overview
11.5.3 Optomed Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.5.4 Optomed Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.5.5 Optomed Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Product in 2024
11.5.6 Optomed Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Application in 2024
11.5.7 Optomed Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Geographic Area in 2024
11.5.8 Optomed Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
11.5.9 Optomed Recent Developments
11.6 Sibionics Technology
11.6.1 Sibionics Technology Corporation Information
11.6.2 Sibionics Technology Business Overview
11.6.3 Sibionics Technology Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.6.4 Sibionics Technology Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.6.5 Sibionics Technology Recent Developments
11.7 Aeye Health
11.7.1 Aeye Health Corporation Information
11.7.2 Aeye Health Business Overview
11.7.3 Aeye Health Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.7.4 Aeye Health Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.7.5 Aeye Health Recent Developments
11.8 VUNO
11.8.1 VUNO Corporation Information
11.8.2 VUNO Business Overview
11.8.3 VUNO Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.8.4 VUNO Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.8.5 VUNO Recent Developments
11.9 Medimaging Integrated Solution
11.9.1 Medimaging Integrated Solution Corporation Information
11.9.2 Medimaging Integrated Solution Business Overview
11.9.3 Medimaging Integrated Solution Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.9.4 Medimaging Integrated Solution Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.9.5 Medimaging Integrated Solution Recent Developments
11.10 EyRIS (SELENA+)
11.10.1 EyRIS (SELENA+) Corporation Information
11.10.2 EyRIS (SELENA+) Business Overview
11.10.3 EyRIS (SELENA+) Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.10.4 EyRIS (SELENA+) Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Vistel
11.11.1 Vistel Corporation Information
11.11.2 Vistel Business Overview
11.11.3 Vistel Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.11.4 Vistel Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.11.5 Vistel Recent Developments
11.12 RETINA-AI Health
11.12.1 RETINA-AI Health Corporation Information
11.12.2 RETINA-AI Health Business Overview
11.12.3 RETINA-AI Health Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.12.4 RETINA-AI Health Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.12.5 RETINA-AI Health Recent Developments
11.13 Acer Medical
11.13.1 Acer Medical Corporation Information
11.13.2 Acer Medical Business Overview
11.13.3 Acer Medical Age-Related Macular Degeneration (AMD) AI Screening System Product Features and Attributes
11.13.4 Acer Medical Age-Related Macular Degeneration (AMD) AI Screening System Revenue and Gross Margin (2020-2025)
11.13.5 Acer Medical Recent Developments
12 Age-Related Macular Degeneration (AMD) AI Screening SystemIndustry Chain Analysis
12.1 Age-Related Macular Degeneration (AMD) AI Screening System Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Age-Related Macular Degeneration (AMD) AI Screening System Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Age-Related Macular Degeneration (AMD) AI Screening System Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
 Table 1. Global Age-Related Macular Degeneration (AMD) AI Screening System Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Age-Related Macular Degeneration (AMD) AI Screening System Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Age-Related Macular Degeneration (AMD) AI Screening System by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-Related Macular Degeneration (AMD) AI Screening System as of 2024)
 Table 11. Global Age-Related Macular Degeneration (AMD) AI Screening System Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Age-Related Macular Degeneration (AMD) AI Screening System Companies Headquarters
 Table 13. Global Age-Related Macular Degeneration (AMD) AI Screening System Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Age-Related Macular Degeneration (AMD) AI Screening System High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Age-Related Macular Degeneration (AMD) AI Screening System Growth Accelerators and Market Barriers
 Table 25. North America Age-Related Macular Degeneration (AMD) AI Screening System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Age-Related Macular Degeneration (AMD) AI Screening System Growth Accelerators and Market Barriers
 Table 27. Europe Age-Related Macular Degeneration (AMD) AI Screening System Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Age-Related Macular Degeneration (AMD) AI Screening System Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Age-Related Macular Degeneration (AMD) AI Screening System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Age-Related Macular Degeneration (AMD) AI Screening System Investment Opportunities and Key Challenges
 Table 31. Central and South America Age-Related Macular Degeneration (AMD) AI Screening System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Age-Related Macular Degeneration (AMD) AI Screening System Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Age-Related Macular Degeneration (AMD) AI Screening System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Airdoc Technology Corporation Information
 Table 35. Airdoc Technology Description and Major Businesses
 Table 36. Airdoc Technology Product Features and Attributes
 Table 37. Airdoc Technology Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Airdoc Technology Revenue Proportion by Product in 2024
 Table 39. Airdoc Technology Revenue Proportion by Application in 2024
 Table 40. Airdoc Technology Revenue Proportion by Geographic Area in 2024
 Table 41. Airdoc Technology Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
 Table 42. Airdoc Technology Recent Developments
 Table 43. Digital Diagnostics Corporation Information
 Table 44. Digital Diagnostics Description and Major Businesses
 Table 45. Digital Diagnostics Product Features and Attributes
 Table 46. Digital Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Digital Diagnostics Revenue Proportion by Product in 2024
 Table 48. Digital Diagnostics Revenue Proportion by Application in 2024
 Table 49. Digital Diagnostics Revenue Proportion by Geographic Area in 2024
 Table 50. Digital Diagnostics Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
 Table 51. Digital Diagnostics Recent Developments
 Table 52. Eyenuk Corporation Information
 Table 53. Eyenuk Description and Major Businesses
 Table 54. Eyenuk Product Features and Attributes
 Table 55. Eyenuk Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Eyenuk Revenue Proportion by Product in 2024
 Table 57. Eyenuk Revenue Proportion by Application in 2024
 Table 58. Eyenuk Revenue Proportion by Geographic Area in 2024
 Table 59. Eyenuk Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
 Table 60. Eyenuk Recent Developments
 Table 61. RetinaLyze System Corporation Information
 Table 62. RetinaLyze System Description and Major Businesses
 Table 63. RetinaLyze System Product Features and Attributes
 Table 64. RetinaLyze System Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. RetinaLyze System Revenue Proportion by Product in 2024
 Table 66. RetinaLyze System Revenue Proportion by Application in 2024
 Table 67. RetinaLyze System Revenue Proportion by Geographic Area in 2024
 Table 68. RetinaLyze System Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
 Table 69. RetinaLyze System Recent Developments
 Table 70. Optomed Corporation Information
 Table 71. Optomed Description and Major Businesses
 Table 72. Optomed Product Features and Attributes
 Table 73. Optomed Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Optomed Revenue Proportion by Product in 2024
 Table 75. Optomed Revenue Proportion by Application in 2024
 Table 76. Optomed Revenue Proportion by Geographic Area in 2024
 Table 77. Optomed Age-Related Macular Degeneration (AMD) AI Screening System SWOT Analysis
 Table 78. Optomed Recent Developments
 Table 79. Sibionics Technology Corporation Information
 Table 80. Sibionics Technology Description and Major Businesses
 Table 81. Sibionics Technology Product Features and Attributes
 Table 82. Sibionics Technology Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Sibionics Technology Recent Developments
 Table 84. Aeye Health Corporation Information
 Table 85. Aeye Health Description and Major Businesses
 Table 86. Aeye Health Product Features and Attributes
 Table 87. Aeye Health Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Aeye Health Recent Developments
 Table 89. VUNO Corporation Information
 Table 90. VUNO Description and Major Businesses
 Table 91. VUNO Product Features and Attributes
 Table 92. VUNO Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. VUNO Recent Developments
 Table 94. Medimaging Integrated Solution Corporation Information
 Table 95. Medimaging Integrated Solution Description and Major Businesses
 Table 96. Medimaging Integrated Solution Product Features and Attributes
 Table 97. Medimaging Integrated Solution Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Medimaging Integrated Solution Recent Developments
 Table 99. EyRIS (SELENA+) Corporation Information
 Table 100. EyRIS (SELENA+) Description and Major Businesses
 Table 101. EyRIS (SELENA+) Product Features and Attributes
 Table 102. EyRIS (SELENA+) Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. EyRIS (SELENA+) Recent Developments
 Table 104. Vistel Corporation Information
 Table 105. Vistel Description and Major Businesses
 Table 106. Vistel Product Features and Attributes
 Table 107. Vistel Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Vistel Recent Developments
 Table 109. RETINA-AI Health Corporation Information
 Table 110. RETINA-AI Health Description and Major Businesses
 Table 111. RETINA-AI Health Product Features and Attributes
 Table 112. RETINA-AI Health Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. RETINA-AI Health Recent Developments
 Table 114. Acer Medical Corporation Information
 Table 115. Acer Medical Description and Major Businesses
 Table 116. Acer Medical Product Features and Attributes
 Table 117. Acer Medical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Acer Medical Recent Developments
 Table 119. Raw Materials Key Suppliers
 Table 120. Distributors List
 Table 121. Market Trends and Market Evolution
 Table 122. Market Drivers and Opportunities
 Table 123. Market Challenges, Risks, and Restraints
 Table 124. Research Programs/Design for This Report
 Table 125. Key Data Information from Secondary Sources
 Table 126. Key Data Information from Primary Sources


List of Figures
 Figure 1. Age-Related Macular Degeneration (AMD) AI Screening System Product Picture
 Figure 2. Global Age-Related Macular Degeneration (AMD) AI Screening System Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Hardware Product Picture
 Figure 4. Software Product Picture
 Figure 5. Global Age-Related Macular Degeneration (AMD) AI Screening System Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Medical Institutions
 Figure 7. Great Health Scene
 Figure 8. Age-Related Macular Degeneration (AMD) AI Screening System Report Years Considered
 Figure 9. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 10. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 11. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue Market Share by Region (2020-2031)
 Figure 13. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue Market Share Ranking (2024)
 Figure 14. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 15. Hardware Revenue Market Share by Player in 2024
 Figure 16. Software Revenue Market Share by Player in 2024
 Figure 17. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue Market Share by Type (2020-2031)
 Figure 18. Global Age-Related Macular Degeneration (AMD) AI Screening System Revenue Market Share by Application (2020-2031)
 Figure 19. North America Age-Related Macular Degeneration (AMD) AI Screening System Revenue YoY (2020-2031) & (US$ Million)
 Figure 20. North America Top 5 Players Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) in 2024
 Figure 21. North America Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Type (2020 - 2031)
 Figure 22. North America Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Application (2020-2031)
 Figure 23. US Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 24. Canada Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 25. Mexico Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 26. Europe Age-Related Macular Degeneration (AMD) AI Screening System Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. Europe Top 5 Players Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) in 2024
 Figure 28. Europe Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Type (2020-2031)
 Figure 29. Europe Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Application (2020-2031)
 Figure 30. Germany Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 31. France Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 32. U.K. Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 33. Italy Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 34. Russia Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Age-Related Macular Degeneration (AMD) AI Screening System Revenue YoY (2020-2031) & (US$ Million)
 Figure 36. Asia-Pacific Top 8 Players Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) in 2024
 Figure 37. Asia-Pacific Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Type (2020-2031)
 Figure 38. Asia-Pacific Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Application (2020-2031)
 Figure 39. Indonesia Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 40. Japan Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 41. South Korea Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 42. Australia Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 43. India Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 44. Indonesia Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 45. Vietnam Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 46. Malaysia Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 47. Philippines Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 48. Singapore Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2031) & (US$ Million)
 Figure 49. Central and South America Age-Related Macular Degeneration (AMD) AI Screening System Revenue YoY (2020-2031) & (US$ Million)
 Figure 50. Central and South America Top 5 Players Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) in 2024
 Figure 51. Central and South America Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Type (2020-2031)
 Figure 52. Central and South America Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Application (2020-2031)
 Figure 53. Brazil Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2025) & (US$ Million)
 Figure 54. Argentina Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2025) & (US$ Million)
 Figure 55. Middle East and Africa Age-Related Macular Degeneration (AMD) AI Screening System Revenue YoY (2020-2031) & (US$ Million)
 Figure 56. Middle East and Africa Top 5 Players Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) in 2024
 Figure 57. South America Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Type (2020-2031)
 Figure 58. Middle East and Africa Age-Related Macular Degeneration (AMD) AI Screening System Revenue (US$ Million) by Application (2020-2031)
 Figure 59. GCC Countries Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2025) & (US$ Million)
 Figure 60. Israel Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2025) & (US$ Million)
 Figure 61. Egypt Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2025) & (US$ Million)
 Figure 62. South Africa Age-Related Macular Degeneration (AMD) AI Screening System Revenue (2020-2025) & (US$ Million)
 Figure 63. Age-Related Macular Degeneration (AMD) AI Screening System Industry Chain Mapping
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS